RxDoctor Payments Data

Angela Kirkendall, NP

Family · Kokomo, INNPI 1114576097

Payments from drug & device makers

$607in general payments, 2019–2025

Across 11 payments — averaging $55.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$164
  • Tris Pharma Inc$123
  • Phathom Pharmaceuticals, Inc.$115
  • Exact Sciences$95
  • Lilly USA, LLC$52
  • Genentech USA, Inc.$24
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$607 in reported general payments places this provider in the 55th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$45,309
Medicare patients
209
Services billed
605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide19$40,463
OzempicSemaglutide32$37,590
JardianceEmpagliflozin14$21,234
MyrbetriqMirabegron15$10,304
LinzessLinaclotide12$7,975
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen117$2,000
Albuterol Sulfate HfaAlbuterol Sulfate65$1,931
Atorvastatin Calcium147$1,357
Celecoxib11$1,252
Gabapentin83$1,225
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,190
SynthroidLevothyroxine Sodium29$1,150
Lidocaine15$1,119
Losartan Potassium85$1,067
Duloxetine Hcl48$955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$52$40,46319 claims
Novo NordiskOzempic$164$37,59032 claims
AbbVieLinzess, Synthroid, Armour Thyroid$15$9,76452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,392 family providers in Indiana.

Other family in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →